JPRN-jRCT2080220900未知1 期
Safety and efficacy of TBI-0301 gene-transduced donor lymphocyte infusion in patients with hematological malignancy experiencing recurrence/relapse or aggravation after allogeneic hematopoietic stem-cell transplantation
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable(—)
- 性别
- All
入选标准
- •(1)Patients with a diagnosis of relapse, recurrence or aggravation of hematological malignancy after related allogeneic stem cell transplantation
- •(2)Patients should be > 20 years old
- •(3)ECOG performance status (PS) 0 to 2
- •(4)No severe organ damage as measured by:
- •-Oxygen saturation > 93 % (non-invasive measurement is acceptable)
- •-AST (GOT) and ALT (GPT) < 5 X ULN
- •-Total bilirubin and serum creatinine < 3 X ULN
- •-Physically normal electrocardiogram
- •(1)Original donor of hematopoietic stem cell transplantation
- •(2)Donor should be > 20, < 65 years old
- •(3)ECOG performance status (PS) 0
- •(4)Having a good heart, lung, liver and kidney function
- •-No ischemic electrocardiographic changes and no arrhythmia requiring treatment on ischemic
- •-Chest x-ray without evidence of active infection, and arterial oxygen saturation > 93% without oxygen administration (non-invasive measurement is acceptable)
- •-Serum creatinine < 1.5 mg/dL
- •-AST (GOT) , ALT (GPT), and total serum bilirubin < 2 X ULN
- •(5)Having a good hematopoietic capacity
- •-WBC > 3,000 /microliter, PLT > 130,000 /microliter
- •-Hb > 13.0 g/dL for men, 11.0 g/dL for women
排除标准
- •(1)Relapsed, recurrent or aggravated patients in very early after transplantation who can not expect the effect of donor lymphocyte infusion.
- •(2)Patients with Epstein-Barr virus- associated lymphoproliferative disorder
- •(3)Presence of grade II to IV acute GVHD or extensive chronic GVHD
- •(4)LVEF at rest < 50 %
- •(5)Patients with central nervous system involvement
- •(6)Patients with multiple malignancies
- •(7)Patients with active infection
- •(8)Ongoing GCV, acyclovir or valacyclovir administration within 24 hours before the infusion of donor lymphocytes transduced with TBI-0301
- •(1)Presence of complication and medical history listed below:
- •-Autoimmune disease (include collagen disease)
- •-Phlebothrombosis, arteriosclerotic disease
- •-Congestive heart failure, ischemic Heart failure, cerebrovascular lesion
- •-Interstitial pneumonia
- •-Malignant tumor
- •(2)Diabetes uncontrollable even with regular insulin use, or uncontrollable hypertension
- •(3)History of grave drug allergy
- •(4)Pregnant or lactating women
- •(5)Any of the HBs antigen, HCV antibody and HIV antibody, and serological test for syphilis positivity
- •(6)Uncontrollable mental illness
研究者
相似试验
进行中(未招募)
1 期
Prospective study on safety and efficacy of gene therapy with voretigene neparvovec (Luxturna®) in patients with RPE65-associated inherited retinal degenerationsEUCTR2021-000265-33-NLThe Rotterdam Eye Hospital20
尚未招募
不适用
Prospective study on safety and efficacy of gene therapy with voretigene neparvovec (Luxturna®) in patients with RPE65-associated inherited retinal degenerationsRPE65-associated inherited retinal degenerations (IRDs).NL-OMON22976The Rotterdam Eye Hospital20
招募中
不适用
Prospective study on safety and efficacy of gene therapy with voretigene neparvovec (Luxturna®) in patients with RPE65-associated inherited retinal degenerationsRPE65-associated inherited retinal degenerations10010463NL-OMON50929Oogziekenhuis Rotterdam20
招募中
3 期
Study of Out of Specification for TisagenlecleucelPediatric/young adult patients with r/r pALL and adult patients with r/r LBCL (including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma) for Part 1, and r/r ALL and r/r NHL for Part 2.JPRN-jRCT1080224903ovartis Pharma. K.K.200
已完成
不适用
Evaluation of efficacy and safety profiles of tribulus terristrus in males with partial androgen deficiency and erectile dysfunction and lower urinary tract symptoms in a placebo controlled studypartial androgen deficiency with erectile dysfunction and low libidoJPRN-UMIN000023070cairo university70
